Pharmaceutical Sciences

Pharmaceutical Sciences Experts

Torsten Dreier

Chief Development Officer
Board of Directors


Torsten Dreier has been developing antibodies for more than 20 years and progressed six antibody products from preclinical research into clinical trials. Prior to joining argenx, he was Director of Therapeutic Drug Development and Senior Director Preclinical Development at Ablynx NV, with overall responsibility for pharmacology, toxicology, bioanalytics and CMC as well as early clinical development. Between 1997-2003, Dr. Dreier worked as Director Preclinical Development at Micromet AG in Munich, Germany, on the preclinical characterization of recombinant antibodies and BiTEs® (bispecific T cell engagers).

Research Interest

He holds a PhD in Biochemistry from the University of Tübingen, Germany. In 1995, he joined the group of Prof. Ralf A. Reisfeld at the Scripps Research Institute in La Jolla, CA as a postdoctoral researcher and extended his know-how in immunology with his work on immunocytokines (recombinant antibody cytokine fusion proteins), recombinant antibodies and cytokines.

Global Experts from Belgium

Global Experts in Subject

Share This Profile
Recommended Conferences
  • 6th European Biopharma Congress

    September 18-19, 2018 Amsterdam, Netherlands

  • 5th International Conference on Pain Medicine and Pain Management

    October 17-18, 2018 New York, USA

  • 18th World Pharma Congress

    October 18-19, 2018 Warsaw, Poland

  • 18th World Pharma Congress

    October 18-20, 2018 Warsaw, Poland

  • 13th International Conference on Biosimilars and Biologics

    November 14-15, 2018 Lisbon, Portugal

View more
Relevant Topics